NCTId,final_date,start_date,change,final_value,start_value
NCT06917430,2025-04-14 07:23:54.936232,,New  Study  Added,,
NCT01247207,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-11,2025-01-08
NCT01247207,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-11
NCT01247207,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-11,2025-03-25
NCT01633866,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2024-12-16
NCT01633866,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2024-12-16,2025-03-25
NCT01999075,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Results First Post Date,2025-03-25,2025-01-09
NCT01999075,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-09
NCT01999075,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Results First Post Date,2025-01-09,2025-03-25
NCT01999075,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-09,2025-03-25
NCT02069756,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Last Update Post Date,2025-02-10,2023-09-13
NCT02069756,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-10
NCT02069756,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-10,2025-03-25
NCT02369731,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Last Update Post Date,2025-03-14,2025-01-28
NCT02369731,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-14
NCT02369731,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-14,2025-03-25
NCT02413450,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-31
NCT02413450,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-31,2025-03-25
NCT02470962,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Brief Title,Cardiac Involvement in Patients with Duchenne/Becker Muscular Dystrophy,Cardiac Involvement in Patients With Duchenne/Becker Muscular Dystrophy
NCT02470962,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Overall Status,COMPLETED,UNKNOWN
NCT02470962,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Enrollment Count,59.0,40.0
NCT02470962,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Start Date,2015-06-01,2015-05-01
NCT02470962,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Primary Completion Date,2022-03-22,2020-04-01
NCT02470962,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Completion Date,2022-03-22,2020-04-01
NCT02470962,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Last Update Post Date,2025-03-20,2019-07-12
NCT02470962,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-20
NCT02470962,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-20,2025-03-25
NCT02484560,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Collaborator Name,Istinye University,"Istınye University, Cukurova University, Yıldırım Beyazıt University, Gaziantep Deva Hospital, Gaziantep Public Hospital"
NCT02485938,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Results First Post Date,2025-03-25,2025-01-09
NCT02485938,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-09
NCT02485938,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Results First Post Date,2025-01-09,2025-03-25
NCT02485938,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-09,2025-03-25
NCT02500381,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2024-12-16
NCT02500381,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2024-12-16,2025-03-25
NCT03057002,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Overall Status,COMPLETED,RECRUITING
NCT03057002,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Condition,"Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure with Preserved Ejection Fraction, Heart Failure with Reduced Ejection Fraction","Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction"
NCT03057002,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Enrollment Count,7.0,128.0
NCT03057002,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Primary Completion Date,2023-05-17,2025-03-08
NCT03057002,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Completion Date,2023-05-17,2025-03-08
NCT03057002,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-26,2024-12-16
NCT03333590,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Overall Status,COMPLETED,ACTIVE_NOT_RECRUITING
NCT03333590,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Completion Date,2023-12-31,2023-10-01
NCT03333590,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-13,2023-09-14
NCT03333590,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-13
NCT03333590,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-13,2025-03-25
NCT03340675,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Primary Completion Date,2025-09-01,2025-01-31
NCT03340675,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Completion Date,2025-12-01,2025-01-31
NCT03340675,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Last Update Post Date,2025-02-12,2025-01-24
NCT03340675,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-12
NCT03340675,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-12,2025-03-25
NCT03362502,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Enrollment Count,23.0,22.0
NCT03362502,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Completion Date,2025-05-30,2026-03-30
NCT03362502,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Last Update Post Date,2025-02-21,2024-09-20
NCT03362502,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-21
NCT03362502,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-21,2025-03-25
NCT03368742,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-06
NCT03368742,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-06,2025-03-25
NCT03406780,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Brief Summary,HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne Muscular Dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.,HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.
NCT03406780,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Has Results,True,False
NCT03406780,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Primary Outcome Measure,"Change From Baseline in Functional Capacity as Assessed by the Mid-level (Elbow) Dimension Score of the Performance of Upper Limb (PUL) Version 1.2 at Month 12, Number of Participants Experiencing Acute Respiratory Decompensation, Number of Participants With Hypersensitivity Reactions, Number of Participants With All-cause Mortality, Number of Participants With Serious Adverse Events (SAEs), Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Investigational Product (IP) or Administration Procedure, Number of Participants With Immune Sensitization Syndrome",Change in the mid-level (elbow) dimension of the Performance of the Upper Limb (PUL)
NCT03406780,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Secondary Outcome Measure,"Number of Participants With TEAEs and Severity of TEAEs, Change From Baseline in the Mid-level (Elbow) Dimension Score of the PUL 1.2 at Months 3, 6, and 9, Change From Baseline in Regional Systolic Left Ventricular (LV) Wall Thickening, as Assessed by Cardiac Magnetic Resonance Imaging (MRI) at Months 6 and 12","Change in the mid-level (elbow) dimension of the PUL, Change in regional systolic left ventricular wall thickening as assessed by cardiac MRI"
NCT03406780,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Enrollment Count,20.0,18.0
NCT03406780,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Start Date,2018-04-04,2018-03-04
NCT03406780,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Last Update Post Date,2025-02-24,2020-06-05
NCT03406780,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Results First Post Date,2025-03-25,2025-02-24
NCT03406780,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-24
NCT03406780,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Results First Post Date,2025-02-24,2025-03-25
NCT03406780,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-24,2025-03-25
NCT03655223,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Secondary Id,HHSN27500003,"U01TR001792-01, HHSN27500003"
NCT03655223,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Primary Completion Date,2025-11-30,2024-11-30
NCT03655223,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-04-04,2024-03-27
NCT03836300,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Primary Completion Date,2026-06-30,2024-12-31
NCT03836300,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Completion Date,2026-12-31,2025-06-30
NCT03836300,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Last Update Post Date,2025-04-06,2024-05-01
NCT03863119,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Overall Status,APPROVED_FOR_MARKETING,AVAILABLE
NCT03863119,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Last Update Post Date,2025-02-10,2023-11-09
NCT03863119,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-10
NCT03863119,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-10,2025-03-25
NCT03947112,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Brief Title,Physical Activity Level of Norwegian Boys with Duchenne Muscular Dystrophy,Physical Activity Level of Norwegian Boys With Duchenne Muscular Dystrophy
NCT03947112,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Last Update Post Date,2025-03-05,2021-12-29
NCT03947112,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-05
NCT03947112,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-05,2025-03-25
NCT03963453,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Last Update Post Date,2025-03-05,2023-03-01
NCT03963453,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-05
NCT03963453,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-05,2025-03-25
NCT03992430,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2024-12-20
NCT03992430,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2024-12-20,2025-03-25
NCT04004065,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Brief Title,"Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment","Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment"
NCT04004065,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Overall Status,TERMINATED,ACTIVE_NOT_RECRUITING
NCT04004065,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Completion Date,2025-02-07,2029-01-31
NCT04004065,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-10,2024-10-30
NCT04004065,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-10
NCT04004065,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-10,2025-03-25
NCT04281485,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-13
NCT04281485,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-13,2025-03-25
NCT04322357,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Overall Status,ACTIVE_NOT_RECRUITING,RECRUITING
NCT04322357,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Primary Completion Date,2025-09-05,2025-01-05
NCT04322357,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Last Update Post Date,2025-02-27,2024-11-06
NCT04322357,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-27
NCT04322357,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-27,2025-03-25
NCT04428476,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Has Results,True,False
NCT04428476,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Primary Outcome Measure,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From Baseline Through Month 12, Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity From Baseline Through Month 12, Change From Baseline in Functional Capacity as Assessed by Performance of the Upper Limb Test, Version 2 (PUL 2.0) Total Score.","The primary safety endpoint is the incidence and severity of all treatment-emergent adverse events, The primary efficacy endpoint is change in upper limb function"
NCT04428476,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Secondary Outcome Measure,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) at Month 24, Month 36, Month 48 and Month 60, Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity From Baseline Through Month 60, Change From Baseline in Upper Limb Function as Assessed by Performance of the Upper Limb Test, Version 2 (PUL 2.0) at Month 12, Month 24, Month 36, Month 48, and Month 60, Change From Baseline in Distal-Level (Wrist and Hand) Upper Limb Function as Assessed by Performance of the Upper Limb Test, Version 2 (PUL 2.0) at Month 12, Month 24, Month 36, Month 48, and Month 60, Change From Baseline in Mid-Level (Elbow) as Assessed by Performance of the Upper Limb Test, Version 2 (PUL 2.0) at Month 12, Month 24, Month 36, Month 48, and Month 60, Change From Baseline in Cardiac Parameter: Left Ventricular Ejection Fraction (LVEF) at Month, 24, 36, 48, and 60, Change From Baseline in Cardiac Parameter: Left Ventricular End Systolic Volumes-Indexed (LV-ESVI) at Month 24, Month 36, Month 48, and Month 60, Change From Baseline in Cardiac Parameter: Left Ventricular End Diastolic Volumes-Indexed (LV-EDVI) at Month 24, Month 36, Month 48, and Month 60, Change From Baseline in Cardiac Parameter: Left Ventricle Mass (LV Mass) at Month 24, Month 36, Month 48, and Month 60, Change From Baseline in Cardiac Parameter: Unindexed Volumes at Month 24, Month 36, Month 48, and Month 60, Change From Baseline in Cardiac Parameter: Left Ventricle End Diastolic Wall Thickening (LVEDWT) at Month 24, Month 36, Month 48, and Month 60, Change From Baseline in Cardiac Parameter: Left Ventricle End Systolic Wall Thickening (LVESWT) at Month 24, Month 36, Month 48, and Month 60","Incidence and severity of all treatment-emergent adverse events, Change from baseline in upper limb function, Change from from baseline in distal-level (wrist and hand) upper limb function, Change from baseline in mid-level (elbow) upper limb function, Change in cardiac muscle function and structure by assessment of Left Ventricular Ejection Fraction (LVEF), Change in cardiac muscle function and structure by assessment of Left Ventricular End Systolic Volumes-Indexed (ESVI), Change in cardiac muscle function and structure by assessment of Left Ventricular End Diastolic Volumes-Indexed (EDVI), Change in cardiac muscle function and structure by assessment of mass, Change in cardiac muscle function and structure by assessment of unindexed volumes, Change in cardiac muscle function and structure by assessment of cardiac output, Change in cardiac muscle function and structure by assessment of wall thickening percentage, Change in cardiac muscle function and structure by assessment of end diastolic wall thickness, Change in cardiac muscle function and structure by assessment of end systolic wall thickness"
NCT04428476,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Start Date,2020-08-05,2020-07-20
NCT04428476,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Last Update Post Date,2025-02-24,2024-11-12
NCT04428476,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Results First Post Date,2025-03-25,2025-02-24
NCT04428476,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-24
NCT04428476,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Results First Post Date,2025-02-24,2025-03-25
NCT04428476,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-24,2025-03-25
NCT04529707,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Brief Title,Sleep Intervention in Young Boys with Duchenne Muscular Dystrophy,Sleep Intervention in Young Boys With Duchenne Muscular Dystrophy
NCT04529707,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Overall Status,COMPLETED,RECRUITING
NCT04529707,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Enrollment Count,38.0,100.0
NCT04529707,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Primary Completion Date,2024-10-31,2025-12-31
NCT04529707,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Completion Date,2024-12-31,2026-08-31
NCT04529707,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Last Update Post Date,2025-03-07,2024-03-05
NCT04529707,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-07
NCT04529707,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-07,2025-03-25
NCT04906460,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Brief Title,Open-label Study of WVE-N531 in Patients with Duchenne Muscular Dystrophy (FORWARD-53),Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
NCT04906460,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Brief Summary,"This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 2 parts, Part A and Part B. Part A is completed. Part B is completed. Following completion of Part B, all patients have elected to continue to receive study drug in an optional open-label extension arm.","This is a Phase 1b/2a open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 2 parts, Part A and Part B. Part A is complete."
NCT04906460,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Primary Completion Date,2025-01-16,2025-01-01
NCT04906460,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Completion Date,2026-10-01,2025-05-01
NCT04906460,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Last Update Post Date,2025-02-19,2024-02-28
NCT04906460,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-19
NCT04906460,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-19,2025-03-25
NCT05126758,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-04
NCT05126758,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-04,2025-03-25
NCT05166109,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2024-12-27
NCT05166109,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2024-12-27,2025-03-25
NCT05195775,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Primary Completion Date,2025-09-05,2025-01-20
NCT05195775,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Completion Date,2025-09-05,2025-01-20
NCT05195775,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Last Update Post Date,2025-02-27,2024-11-06
NCT05195775,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-27
NCT05195775,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-27,2025-03-25
NCT05257473,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-10,2024-11-04
NCT05257473,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-10
NCT05257473,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-10,2025-03-25
NCT05257473,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Overall Status,ACTIVE_NOT_RECRUITING,RECRUITING
NCT05257473,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Primary Completion Date,2026-05-01,2025-05-01
NCT05257473,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Last Update Post Date,2025-04-06,2025-03-10
NCT05280730,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Primary Completion Date,2025-04-30,2024-12-01
NCT05280730,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Completion Date,2025-04-30,2024-12-01
NCT05280730,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-26,2024-04-16
NCT05291091,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Enrollment Count,175.0,170.0
NCT05291091,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Primary Completion Date,2026-08-01,2026-06-01
NCT05291091,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Completion Date,2026-08-01,2026-06-01
NCT05291091,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Last Update Post Date,2025-03-04,2025-02-05
NCT05291091,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-04
NCT05291091,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-04-03,2025-03-25
NCT05412394,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Collaborator Name,"Children's Hospital Medical Center, Cincinnati, Muscular Dystrophy Association, University of Texas, Virginia Commonwealth University, Ann & Robert H Lurie Children's Hospital of Chicago","Ann & Robert H Lurie Children's Hospital of Chicago, Children's Hospital Medical Center, Cincinnati, Muscular Dystrophy Association, University of Texas, Virginia Commonwealth University"
NCT05412394,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Primary Completion Date,2026-08-01,2026-08-30
NCT05412394,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Completion Date,2026-12-01,2026-12-30
NCT05412394,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Last Update Post Date,2025-02-13,2023-09-18
NCT05412394,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-13
NCT05412394,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-13,2025-03-25
NCT05429372,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Primary Completion Date,2025-05-30,2024-12-27
NCT05429372,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Last Update Post Date,2025-03-04,2024-04-04
NCT05429372,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-04
NCT05429372,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-04,2025-03-25
NCT05516745,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Overall Status,UNKNOWN,RECRUITING
NCT05524883,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-22
NCT05524883,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-22,2025-03-25
NCT05540860,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2024-12-27
NCT05540860,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2024-12-27,2025-03-25
NCT05558813,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-03
NCT05558813,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-03,2025-03-25
NCT05670730,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Overall Status,COMPLETED,ACTIVE_NOT_RECRUITING
NCT05670730,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Enrollment Count,70.0,64.0
NCT05670730,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Primary Completion Date,2024-11-25,2025-01-01
NCT05670730,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Completion Date,2024-11-25,2025-01-01
NCT05670730,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-11,2024-09-23
NCT05670730,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-11
NCT05670730,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-11,2025-03-25
NCT05683379,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Primary Completion Date,2026-09-01,2024-12-01
NCT05683379,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Completion Date,2026-09-01,2024-12-01
NCT05683379,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Last Update Post Date,2025-04-06,2024-07-18
NCT05689164,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-07
NCT05689164,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-07,2025-03-25
NCT05693142,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-12,2025-01-20
NCT05693142,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-12
NCT05693142,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-12,2025-03-25
NCT05849688,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Overall Status,UNKNOWN,NOT_YET_RECRUITING
NCT05881408,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Last Update Post Date,2025-02-17,2025-01-22
NCT05881408,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-17
NCT05881408,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-17,2025-03-25
NCT05933057,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-27,2024-12-09
NCT05938023,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-03
NCT05938023,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-03,2025-03-25
NCT05967351,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-17
NCT05967351,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-17,2025-03-25
NCT05982119,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Brief Title,Assessments in Patients with Muscular Pathology and in Control Subjects : the ActiLiège Next Study,Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
NCT05982119,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Maximum Age,80 Years,100 Years
NCT05982119,2025-02-17 07:20:41.747565,2025-02-10 07:20:33.372640,Last Update Post Date,2025-02-12,2024-05-30
NCT05982119,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-12
NCT05982119,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-12,2025-03-25
NCT06053814,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2024-12-17
NCT06053814,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2024-12-17,2025-03-25
NCT06054971,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Overall Status,COMPLETED,RECRUITING
NCT06054971,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Enrollment Count,31.0,30.0
NCT06054971,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Primary Completion Date,2025-02-03,2024-05-01
NCT06054971,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Completion Date,2025-03-13,2024-05-01
NCT06054971,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Last Update Post Date,2025-03-21,2023-11-22
NCT06054971,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-21
NCT06054971,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-21,2025-03-25
NCT06066580,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Enrollment Count,260.0,200.0
NCT06066580,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Primary Completion Date,2029-08-01,2028-03-01
NCT06066580,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Completion Date,2029-08-01,2028-03-01
NCT06066580,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-11,2024-12-17
NCT06066580,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-11
NCT06066580,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-11,2025-03-25
NCT06079736,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Overall Status,ACTIVE_NOT_RECRUITING,RECRUITING
NCT06079736,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Enrollment Count,7.0,11.0
NCT06079736,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Primary Completion Date,2025-04-01,2025-11-01
NCT06079736,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Completion Date,2027-04-01,2027-11-01
NCT06079736,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Last Update Post Date,2025-03-04,2025-01-07
NCT06079736,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-04
NCT06079736,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-04,2025-03-25
NCT06128564,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Primary Completion Date,2033-05-30,2032-11-30
NCT06128564,2025-02-24 07:20:42.147479,2025-02-17 07:20:41.747565,Last Update Post Date,2025-02-17,2025-01-16
NCT06128564,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Last Update Post Date,2025-03-17,2025-02-17
NCT06128564,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-17
NCT06128564,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-17,2025-03-25
NCT06138639,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-26,2025-02-06
NCT06224660,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Overall Status,RECRUITING,NOT_YET_RECRUITING
NCT06224660,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Start Date,2024-10-02,2024-03-01
NCT06224660,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Primary Completion Date,2027-10-01,2027-02-01
NCT06224660,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Completion Date,2030-10-01,2030-02-01
NCT06224660,2025-03-03 07:22:10.748542,2025-02-24 07:20:42.147479,Last Update Post Date,2025-02-27,2024-01-25
NCT06224660,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-27
NCT06224660,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-27,2025-03-25
NCT06241950,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Primary Completion Date,2026-01-31,2025-01-31
NCT06241950,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Completion Date,2027-10-31,2026-09-30
NCT06241950,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Last Update Post Date,2025-03-03,2024-08-13
NCT06241950,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-03
NCT06241950,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-03,2025-03-25
NCT06244082,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-07
NCT06244082,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-07,2025-03-25
NCT06363526,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Brief Title,Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.,Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
NCT06363526,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Overall Status,ENROLLING_BY_INVITATION,NOT_YET_RECRUITING
NCT06363526,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Secondary Outcome Measure,"Perform an anthropometric study of the patient's characteristics, taking into account weight; and also a general physical examination., Perform an anthropometric study of the patient's characteristics, taking into account age., Perform an anthropometric study of the patient's characteristics, taking into account height., Perform an anthropometric study of the patient's characteristics, taking into account sex., Examine changes in forced expiratory pressure, Analyze changes in maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)., Check if there are changes in the sniff nasal inspiratory pressure (SNIP), Evaluate the fatigue in patients using an EPInfant test., Evaluate the quality of life of patients using a scale called ""Kindscreen-52""., NSAA o North Star Ambulatory Assessment","Perform an anthropometric study of the patient's characteristics, taking into account weight; and also a general physical examination., Perform an anthropometric study of the patient's characteristics, taking into account age., Perform an anthropometric study of the patient's characteristics, taking into account height., Perform an anthropometric study of the patient's characteristics, taking into account sex., Examine changes in forced expiratory pressure, Analyze changes in maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)., Check if there are changes in the sniff nasal inspiratory pressure (SNIP), Evaluate the fatigue in patients using an EPInfant test., Evaluate the quality of life of patients using a scale called ""Kindscreen-52""."
NCT06363526,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Start Date,2025-02-05,2024-05-05
NCT06363526,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Primary Completion Date,2025-07-30,2024-10-30
NCT06363526,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Completion Date,2025-12-30,2024-11-30
NCT06363526,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-26,2024-04-12
NCT06363526,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Brief Title,Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne and Becker Muscular Dystrophies.,Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
NCT06363526,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Secondary Outcome Measure,"Perform an anthropometric study of the patient's characteristics, taking into account weight; and also a general physical examination., Perform an anthropometric study of the patient's characteristics, taking into account age., Perform an anthropometric study of the patient's characteristics, taking into account height., Perform an anthropometric study of the patient's characteristics, taking into account sex., Examine changes in forced expiratory pressure, Analyze changes in maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)., Check if there are changes in the sniff nasal inspiratory pressure (SNIP), Evaluate the fatigue in patients using an EPInfant test., Evaluate the quality of life of patients using a scale called ""Kindscreen-52""., North Star Ambulatory Assessment o NSAA","Perform an anthropometric study of the patient's characteristics, taking into account weight; and also a general physical examination., Perform an anthropometric study of the patient's characteristics, taking into account age., Perform an anthropometric study of the patient's characteristics, taking into account height., Perform an anthropometric study of the patient's characteristics, taking into account sex., Examine changes in forced expiratory pressure, Analyze changes in maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)., Check if there are changes in the sniff nasal inspiratory pressure (SNIP), Evaluate the fatigue in patients using an EPInfant test., Evaluate the quality of life of patients using a scale called ""Kindscreen-52""., NSAA o North Star Ambulatory Assessment"
NCT06363526,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-04-01,2025-03-26
NCT06402942,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Brief Title,Gamified Occupational Therapy for Adolescents with Duchenne Muscular Dystrophy,Gamified Occupational Therapy for Adolescents With Duchenne Muscular Dystrophy
NCT06402942,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Start Date,2025-05-01,2024-09-01
NCT06402942,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Primary Completion Date,2025-08-21,2025-03-21
NCT06402942,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Completion Date,2025-12-08,2025-05-08
NCT06402942,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-12,2024-07-18
NCT06402942,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-12
NCT06402942,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-12,2025-03-25
NCT06412328,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Brief Title,Psychoeducation Program for Parents of Children with Duchenne Muscular Dystrophy,Psychoeducation Program for Parents of Children With DMD
NCT06412328,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-12,2024-05-14
NCT06412328,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Overall Status,ENROLLING_BY_INVITATION,COMPLETED
NCT06412328,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Primary Completion Date,2024-08-29,2023-07-29
NCT06412328,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Completion Date,2026-02-28,2023-08-29
NCT06412328,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-28,2025-03-12
NCT06445985,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-30
NCT06445985,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-30,2025-03-25
NCT06450639,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Start Date,2025-03-31,2025-02-15
NCT06450639,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Last Update Post Date,2025-03-07,2025-02-05
NCT06450639,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-07
NCT06450639,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-07,2025-03-25
NCT06450639,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Start Date,2025-04-04,2025-03-31
NCT06450639,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Last Update Post Date,2025-04-08,2025-03-07
NCT06564974,2025-03-17 07:23:22.697955,2025-03-10 07:19:06.139511,Last Update Post Date,2025-03-11,2024-12-13
NCT06564974,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-11
NCT06564974,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Brief Title,Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.,Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy.
NCT06564974,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-04-02,2025-03-25
NCT06597656,2025-03-10 07:19:06.139511,2025-03-03 07:22:10.748542,Last Update Post Date,2025-03-03,2024-10-16
NCT06597656,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-03
NCT06597656,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-03,2025-03-25
NCT06641895,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Brief Title,Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy,Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients With Duchenne Muscular Dystrophy
NCT06641895,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2024-10-15
NCT06692426,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Overall Status,RECRUITING,NOT_YET_RECRUITING
NCT06692426,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Start Date,2025-03-20,2025-05-16
NCT06692426,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-28
NCT06692426,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-24,2025-03-25
NCT06755138,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-01-01
NCT06755138,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-01
NCT06755138,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-01-01,2025-03-25
NCT06755138,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-01,2025-03-25
NCT06756633,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-01-03
NCT06756633,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-03
NCT06756633,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-01-03,2025-03-25
NCT06756633,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-03,2025-03-25
NCT06769633,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-01-10
NCT06769633,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-24
NCT06769633,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-01-10,2025-03-25
NCT06769633,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-24,2025-03-25
NCT06773988,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-01-14
NCT06773988,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-01-14
NCT06773988,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-01-14,2025-03-25
NCT06773988,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-01-14,2025-03-25
NCT06817382,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-02-10
NCT06817382,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-10
NCT06817382,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-02-10,2025-03-25
NCT06817382,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-10,2025-03-25
NCT06817382,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Overall Status,RECRUITING,NOT_YET_RECRUITING
NCT06817382,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Start Date,2025-05-31,2025-02-07
NCT06817382,2025-04-14 07:23:54.936232,2025-04-07 07:25:06.872251,Last Update Post Date,2025-04-11,2025-02-10
NCT06833489,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-02-18
NCT06833489,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-18
NCT06833489,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-02-18,2025-03-25
NCT06833489,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-18,2025-03-25
NCT06833931,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Overall Status,SUSPENDED,RECRUITING
NCT06833931,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Primary Completion Date,2028-04-30,2027-04-30
NCT06833931,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Completion Date,2030-04-30,2029-04-30
NCT06833931,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Last Update Post Date,2025-03-18,2025-02-19
NCT06833931,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-02-19
NCT06833931,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-18
NCT06833931,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-02-19,2025-03-25
NCT06833931,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-18,2025-03-25
NCT06839469,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-02-21
NCT06839469,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-02-21
NCT06839469,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-02-21,2025-03-25
NCT06839469,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-02-21,2025-03-25
NCT06861270,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-03-06
NCT06861270,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-06
NCT06861270,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-03-06,2025-03-25
NCT06861270,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-06,2025-03-25
NCT06867107,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-03-10
NCT06867107,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-10
NCT06867107,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-03-10,2025-03-25
NCT06867107,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-10,2025-03-25
NCT06868784,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Overall Status,ENROLLING_BY_INVITATION,NOT_YET_RECRUITING
NCT06868784,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Brief Summary,"The effects of Duchenne muscular dystrophy and its treatments on executive functions and occupational performance are under-mentioned in the literature. The researches believe that developmental and cognitive research is needed to identify interventions for children with DMD to identify and adapt to both individual and social environments, including self-care, productivity and leisure activities. Therefore, the aim of this study was to examine executive functions and occupational performance in children with DMD and compare them with healthy controls.","The effects of Duchenne muscular dystrophy and its treatments on executive functions and oculomotor performance are under-mentioned in the literature. We believe that developmental and cognitive research is needed to identify interventions for children with DMD to identify and adapt to both individual and social environments, including self-care, productivity and leisure activities. Therefore, the aim of our study was to examine executive functions and oculomotor performance in children with DMD and compare them with healthy controls."
NCT06868784,2025-03-24 07:24:20.951620,2025-03-17 07:23:22.697955,Last Update Post Date,2025-03-17,2025-03-11
NCT06868784,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-03-11
NCT06868784,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-17
NCT06868784,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-03-11,2025-03-25
NCT06868784,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-17,2025-03-25
NCT06874166,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-03-13
NCT06874166,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-13
NCT06874166,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-03-13,2025-03-25
NCT06874166,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-13,2025-03-25
NCT06887491,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Study First Post Date,2025-03-25,2025-03-20
NCT06887491,2025-03-31 07:23:41.987076,2025-03-24 07:24:20.951620,Last Update Post Date,2025-03-25,2025-03-20
NCT06887491,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Study First Post Date,2025-03-20,2025-03-25
NCT06887491,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-03-20,2025-03-25
NCT06900049,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Brief Title,"Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy","Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients with Duchenne Muscular Dystrophy"
NCT06900049,2025-04-07 07:25:06.872251,2025-03-31 07:23:41.987076,Last Update Post Date,2025-04-02,2025-03-28
